CN109998117A - 调理血压的药食同源食品及制备方法和应用 - Google Patents
调理血压的药食同源食品及制备方法和应用 Download PDFInfo
- Publication number
- CN109998117A CN109998117A CN201910300571.XA CN201910300571A CN109998117A CN 109998117 A CN109998117 A CN 109998117A CN 201910300571 A CN201910300571 A CN 201910300571A CN 109998117 A CN109998117 A CN 109998117A
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- drinking
- integration
- medicinal herbs
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036772 blood pressure Effects 0.000 title claims abstract description 47
- 235000013305 food Nutrition 0.000 title claims abstract description 30
- 230000035622 drinking Effects 0.000 title claims abstract description 20
- 235000008216 herbs Nutrition 0.000 title claims abstract description 20
- 230000010354 integration Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 30
- 239000000284 extract Substances 0.000 claims abstract description 23
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 22
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 21
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 17
- 229930064664 L-arginine Natural products 0.000 claims abstract description 17
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 17
- 229960002173 citrulline Drugs 0.000 claims abstract description 17
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 35
- 241000180649 Panax notoginseng Species 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 12
- 239000009759 San-Chi Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 244000241257 Cucumis melo Species 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 230000003750 conditioning effect Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 5
- 235000000832 Ayote Nutrition 0.000 claims description 4
- 244000036905 Benincasa cerifera Species 0.000 claims description 4
- 235000011274 Benincasa cerifera Nutrition 0.000 claims description 4
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 4
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 4
- 240000001980 Cucurbita pepo Species 0.000 claims description 4
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims description 4
- 240000007049 Juglans regia Species 0.000 claims description 4
- 235000009496 Juglans regia Nutrition 0.000 claims description 4
- 244000300264 Spinacia oleracea Species 0.000 claims description 4
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 235000014571 nuts Nutrition 0.000 claims description 4
- 235000015136 pumpkin Nutrition 0.000 claims description 4
- -1 sorbierite Chemical compound 0.000 claims description 4
- 235000020234 walnut Nutrition 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 244000013123 dwarf bean Species 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 235000007319 Avena orientalis Nutrition 0.000 claims description 2
- 241000209763 Avena sativa Species 0.000 claims description 2
- 235000007558 Avena sp Nutrition 0.000 claims description 2
- 244000241235 Citrullus lanatus Species 0.000 claims description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims description 2
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 claims description 2
- 240000008067 Cucumis sativus Species 0.000 claims description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000302544 Luffa aegyptiaca Species 0.000 claims description 2
- 235000009814 Luffa aegyptiaca Nutrition 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 244000000231 Sesamum indicum Species 0.000 claims description 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 240000001417 Vigna umbellata Species 0.000 claims description 2
- 235000011453 Vigna umbellata Nutrition 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000011812 mixed powder Substances 0.000 claims description 2
- 235000021278 navy bean Nutrition 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 229940080313 sodium starch Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 239000012856 weighed raw material Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 240000004922 Vigna radiata Species 0.000 claims 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 36
- 230000035487 diastolic blood pressure Effects 0.000 description 34
- 230000035488 systolic blood pressure Effects 0.000 description 34
- 235000013376 functional food Nutrition 0.000 description 19
- 206010067482 No adverse event Diseases 0.000 description 13
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 5
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 235000009697 arginine Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960003753 nitric oxide Drugs 0.000 description 5
- 229960003104 ornithine Drugs 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000004132 Ornithine aminotransferases Human genes 0.000 description 2
- 108090000691 Ornithine aminotransferases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000004143 urea cycle Effects 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 101710149674 Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- FFQKYPRQEYGKAF-UHFFFAOYSA-N carbamoyl phosphate Chemical compound NC(=O)OP(O)(O)=O FFQKYPRQEYGKAF-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000021331 green beans Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000019100 sperm motility Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种调理血压的药食同源食品及制备方法和应用,该药食同源食品由硫辛酸、L‑精氨酸、L‑瓜氨酸、三七提取物等构成,其包含多种氨基酸及硫辛酸,制作工艺简便,天然健康,效果优异。该食品制作工艺简便,且具备一定保健效果,配方天然健康。
Description
技术领域
本发明涉及药食同源食品领域,具体涉及一种具有调理血压的药食同源食品,其包含多种氨基酸及硫辛酸,制作工艺简便,天然健康,效果优异。
背景技术
随着环境污染、饮食习惯改变以及城市人群生活压力的增加,高血压已经成为都市中年人群普遍出现的健康问题,并逐渐呈现年轻化、广泛化及全球化的发展趋势。目前具备降血压功效的保健品种类繁多,其功效机理也多种多样,植物来源、西药、膳食纤维、控制Na吸收及软化血管等作用途径均有涉及。
目前对于“三高人群”降血糖、降血压、降血脂的功能食品有很多,但不同产品功效宣称和机理都各异,大多数产品对功效机理的阐述都不太明确,也有一些产品通过混淆概念,引入致泻、破坏肠胃以减少吸收、增加饱腹感以降低摄入等途径达到“减肥”、“降血脂”、“降血压”的效果,但其往往伴随副作用,一些产品通过概念性加入“三七”、“天麻”等中草药粗提物以达到理论功效,其本身的效果往往不太明确,选用原料质量参差不齐,很难保证其品质及功效。
硫辛酸,也称α-硫辛酸,属于维生素B类,具有较强的抗氧化作用。α-硫辛酸在食物中含量很低,因此通过日常饮食补充的效果很有限,据研究,α-硫辛酸的抗氧化作用远远大于维生素C和维生素E。在人体中,α-硫辛酸可以避免维生素C和维生素E的氧化破坏而提高维生素C和维生素E的生理作用,同时,α-硫辛酸参与α-酮酸的氧化脱羧作用,是α-酮酸氧化脱羧酶系的辅酶,而α-酮酸是葡萄糖代谢的产物。因此α-硫辛酸通过参与α-酮酸的氧化脱羧作用而促进葡萄糖的代谢,达到稳定血糖、减缓动脉粥样硬化的作用。
动脉粥样硬化(atherosclerosis,AS),是冠心病、脑梗死、外周血管病的主要原因。脂质代谢障碍为动脉粥样硬化的病变基础,其特点是受累动脉病变从内膜开始,一般先有脂质和复合糖类积聚、出血及血栓形成,进而纤维组织增生及钙质沉着,并有动脉中层的逐渐蜕变和钙化,导致动脉壁增厚变硬、血管腔狭窄。病变常累及大中肌性动脉,一旦发展到足以阻塞动脉腔,则该动脉所供应的组织或器官将缺血或坏死。由于在动脉内膜积聚的脂质外观呈黄色粥样,因此称为动脉粥样硬化。由于α-硫辛酸具有降低血脂、血压、血糖的功效,对于防止动脉粥样硬化也有一定的效果。
一氧化氮NO是一种内皮舒张因子,有利于维持血管的通透性,改善肠道的缺血缺氧功能。NO广泛分布于生物体内各组织中,特别是神经组织中。1992年它被美国Science杂志评选为明星分子。NO是一种极不稳定的生物自由基,其生成依赖于一氧化化氮合成酶(nitric oxide synthase,NOS)并在心、脑血管调节、神经、免疫调节等方面有着十分重要的生物学作用。因此,受到人们的普遍重视。
L-精氨酸(L-Arginine)又称蛋白氨基酸,是氨基酸类化合物。L-精氨酸在人体中通过精氨酸酶分解为尿素和鸟甘酸。鸟甘酸是合成多胺类物质的前体,是调节细胞生长的重要物质,也是细胞增殖的促进剂。通过氧化途径,经一氧化氮合成酶(NOS)催化生成具有生物活性的一氧化氮(NO),L-精氨酸可以由甘氨酸转脒基酶分解为鸟氨酸和肌酐酸,由精氨酸分解酶降解为鸟氨酸和尿素。L-精氨酸在相关酶作用下最终分别转化成腐胺、脯氨酸和谷氨酰胺。腐胺可以生成亚精胺和精胺,三者统称为多胺,谷氨酰胺可进入三羧酸循环,氧化供能产生CO2。L-精氨酸是维持婴幼儿生长发育必不可少的氨基酸。它是鸟氨酸循环的中间代谢物,能促使氨转变成为尿素,从而降低血氨含量。它也是精子蛋白的主要成分,有促进精子生成,提供精子运动能量的作用,因此,L-精氨酸补充剂也非常普遍地应用于食品、保健品领域。
L-瓜氨酸是一种α-氨基酸,是从鸟氨酸及胺基甲酰磷酸盐在尿素循环中生成,或是通过一氧化氮合酶(NOS)催化精氨酸生成NO的副产物。1998年10月12日,诺贝尔委员会将诺贝尔医学奖授予Louis J. lgnarro、Robert F. Furchgott和Ferid Murad博士,以表彰他们发现和证明了“一氧化氮是心血管系统的信号分子”。其研究表明,一氧化氮可以舒张血管平滑肌,从而降低心脑血管疾病的发病率。
大多数循环中的瓜氨酸来自于谷氨酰胺的肠道转化。在某些情况下(如低蛋白饮食时),其他氨基酸如谷氨酸、脯氨酸、精氨酸也可以作为合成瓜氨酸的前体,当肠道功能受损时,瓜氨酸成为一种条件必需氨基酸,肠道吸收的谷氨酸盐在肠黏膜上转化为二氢吡咯-5-羧化物(P5C),此反应由P5C合酶(P5CS)催化;然后经鸟氨酸氨基转移酶(OAT)将其转化为鸟氨酸后,在OCT的作用下合成瓜氨酸。由于催化瓜氨酸分解的ASS和ASL在肠道细胞中的活性很低,所以瓜氨酸不在肠道细胞中分解,而是释放入血。瓜氨酸分解代谢分别在肾脏、产NO细胞和肝脏中进行。在肾脏近端小管细胞中,瓜氨酸通过ASS和ASL的作用,合成精氨酸并释放入血。在产NO的细胞中,瓜氨酸则进入“瓜氨酸—NO”循环发挥作用,在肝细胞中,瓜氨酸可作为前体合成精氨酸,精氨酸又能是生成尿素的前体物质。
由于L-瓜氨酸在在自然界中几乎不存在,而其又是合成精氨酸的前体,通过口服补充L-精氨酸和L-瓜氨酸的方式也成为NO养生法的一部分。研究表明,通过口服补充L-精氨酸的剂量在每日4~7.5g以上时,才能在体内有效产生NO,而同时补充一定量的L-瓜氨酸则可以增强这个效果。现有技术中,对于L-精氨酸的补充产品有很多,但很少按每日4~7.5g足量供应,而L-瓜氨酸的补充产品还并没有太多记载。
发明内容
为解决现有技术中存在的上述问题,本发明提供一种调理血压的药食同源食品及其制备方法和应用。本发明通过如下技术方案实现:
一种调理血压的药食同源食品,按照重量百分比由如下组分原料制成:硫辛酸2~4%;L-精氨酸30~42%;L-瓜氨酸30~42%;三七提取物2~6%;辅料36~6%,各组分含量百分数之和等于100%。
进一步地,所述三七提取物取自三七植物,包括但不限于三七花、三七茎叶的一种或多种。
进一步地,所述L-精氨酸提取自豆类、瓜类、坚果类、谷类,包括但不限于红豆、绿豆、黄豆、黑豆、白芸豆、南瓜、冬瓜子、南瓜子、花生、核桃、燕麦、芝麻的一种或多种。
进一步地,所述L-瓜氨酸提取自瓜类、坚果类,包括但不限于西瓜、丝瓜、冬瓜、南瓜、黄瓜、甜瓜、核桃的一种或多种。
进一步地,所述辅料包括但不限于木糖醇、甘油、山梨醇、阿斯巴甜、三氯蔗糖、山梨酸钾、苯甲酸钠、淀粉和麦芽糊精等常见功能食品辅料中的一种或多种。
进一步地,所述α-硫辛酸提取自菠菜。菠菜是最佳的天然α-硫辛酸提取来源,提取50毫克α-硫辛酸需要 300公斤菠菜,较化学合成的α-硫辛酸活性更高,安全性也更高。
进一步地,本发明还提供了一种所述调理血压的药食同源食品的制备方法,包括以下步骤:
1) 按照权利要求1的比例配备原料,对其中需要粉碎的原料进行粉碎至100-200目;
2) 将上述已称取的原料放入粉末搅拌机搅拌均匀;
3) 成品:将搅拌均匀的混合粉料通过压片机制成片剂,装入包装袋或瓶子,即为成品。
进一步地,所述三七提取物的制备步骤如下:
(1)将三七花或三七茎叶在55℃条件下烘干至恒重;
(2)将烘干后的三七花或三七茎叶粉碎,加入3倍量浓度95%的乙醇,在70℃条件下搅拌2.5h后过滤,收集滤液;
(3)将滤液在70℃条件下减压浓缩,得到浓缩提取液,转移至十万级洁净区内;
(4)洁净区内将减压浓缩提取液喷雾干燥,温度为105℃,喷出速度为0.6 L/s,之后将喷雾干燥收集的固体提取物粉碎,以100目振动筛除去大颗粒,收集筛下物即为三七提取物。
本发明所述降血脂食品在制备调理血压食品中的应用,用量小于3g/天/人,达到调理血压的效果。
与现有技术相比,本发明所提供的调理血压的药食同源食品具有如下优点:
(1)本发明根据诺贝尔奖获得者Louis J. lgnarro提出的NO养生法,克服了NO气体和NO供体药物直接用于预防和治疗疾病的不足,提供了一种通过补充L-精氨酸、L-瓜氨酸来间接在体内合成NO的途径,配合α-硫辛酸和三七提取物,达到协同降血糖、降血压和稳定血压的作用。
(2)本发明中L-精氨酸和L-瓜氨酸是食物中天然存在的两种氨基酸,二者均参与机体尿素循环和NO形成。同时补充L-精氨酸和L-瓜氨酸可以提升体内合成NO的效率,达到舒张血管、缓解动脉粥样硬化和降低血栓形成的效果。
(3)本发明中由于L-精氨酸、L-瓜氨酸、α-硫辛酸和三七提取物的协同作用,使用量小于3g/天/人,达到同样调理血压的效果。
(4)本发明中L-精氨酸、L-瓜氨酸、α-硫辛酸和三七提取物全部取自食材。
(5)本发明本中L-精氨酸、L-瓜氨酸、α-硫辛酸和三七提取物当它们的配比为L-精氨酸30~42%;L-瓜氨酸30~42%;硫辛酸2~4%;三七提取物2~6%时,达到最佳清理血液垃圾的效果,同时调理血压在正常范围,当血压稳定1至2个月,可以停止服用,也可以持续服用,持续服用还能起到提高免疫力,并且无副作用。
具体实施方式
为了更清楚的理解本发明,以下结合发明人给出的依本发明的技术方案所完成的实施例对本发明做进一步的详细说明。本发明并不局限于这些实施例,对本发明所做的任何形式上的变通和/或改变都将落入本发明保护范围。在本发明中,所有的设备或原料等均可从市场获得或是本行业常用的。
实施例1 -4为调理血压的药食同源食品配方
表1 实施例1-4的功能食品配方
实施例5 三七提取物的制备步骤:
(1)将三七花或三七茎叶在55℃条件下烘干至恒重;
(2)将烘干后的三七花或三七茎叶粉碎,加入3倍量浓度95%的乙醇,在70℃条件下搅拌2.5h后过滤,收集滤液;
(3)将滤液在70℃条件下减压浓缩,得到浓缩提取液,转移至十万级洁净区内;
(4)洁净区内将减压浓缩提取液喷雾干燥,温度为105℃,喷出速度为0.6 L/s,之后将喷雾干燥收集的固体提取物粉碎,以100目振动筛除去大颗粒,收集筛下物即为三七提取物。
实施例6-22分别为将实施例4中样品制备成品试用后效果对比如下:
实施例6
马先生,61岁,此前血压为收缩压97mmHg,舒张压152 mmHg,于2016年6月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用1个月后,收缩压89mmHg,舒张压138 mmHg,无不良反应。
实施例7
肖女士,50岁,此前血压为收缩压90mmHg,舒张压145 mmHg,于2016年6月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用1个月后,收缩压80mmHg,舒张压127mmHg,无不良反应。
实施例8
杨先生,72岁,此前血压为收缩压100mmHg,舒张压172mmHg,于2016年6月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用2个月后,收缩压90mmHg,舒张压147 mmHg,无不良反应。
实施例9
黄女士,60岁,此前血压为收缩压84mmHg,舒张压137 mmHg,于2017年3月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用2个月后,收缩压78mmHg,舒张压122 mmHg,无不良反应。
实施例10
白先生,34岁,此前血压为收缩压130mmHg,舒张压165 mmHg,于2017年3月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用4个月后,收缩压90mmHg,舒张压127mmHg,无不良反应。
实施例11
白先生,59岁,此前血压为收缩压110mmHg,舒张压160 mmHg,于2017年3月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用1个月后,收缩压88mmHg,舒张压137mmHg,无不良反应。
实施例12
张先生,48岁,此前血压为收缩压130mmHg,舒张压175 mmHg,于2017年3月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用20天后,收缩压105mmHg,舒张压137mmHg,无不良反应。
实施例13
普先生,48岁,此前血压为收缩压110mmHg,舒张压152mmHg,于2017年3月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用1个月后,收缩压102mmHg,舒张压136mmHg,无不良反应。
实施例14
曾女士,63岁,此前血压为收缩压101mmHg,舒张压147 mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用15天后,收缩压90mmHg,舒张压130mmHg,无不良反应。
实施例15
曾女士,65岁,此前血压为收缩压97mmHg,舒张压142 mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用11天后,收缩压89mmHg,舒张压132 mmHg,无不良反应。
实施例16
李先生,67岁,此前血压为收缩压90mmHg,舒张压148 mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用1个月后,收缩压87mmHg,舒张压138 mmHg,无不良反应。
实施例17
李女士,57岁,此前血压为收缩压88mmHg,舒张压138 mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用7天后,收缩压80mmHg,舒张压121 mmHg,无不良反应。
实施例18
刘先生,53岁,此前血压为收缩压89mmHg,舒张压150 mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用5天后,收缩压86mmHg,舒张压130 mmHg,无不良反应。
实施例19
陈先生,62岁,此前血压为收缩压95mmHg,舒张压156 mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用7天后,收缩压89mmHg,舒张压135 mmHg,无不良反应。
实施例20
孙先生,17岁,此前血压为收缩压92mmHg,舒张压150mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用7天后,收缩压85mmHg,舒张压135 mmHg,无不良反应。
实施例21
石先生,40岁,此前血压为收缩压90mmHg,舒张压155mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用11天后,收缩压89mmHg,舒张压135 mmHg,无不良反应。
实施例22
黄先生,64岁,此前血压为收缩压90mmHg,舒张压147 mmHg,于2017年7月开始服用实施例4所述配方功能食品,每日2次,每次7.5g,服用14天后,收缩压86mmHg,舒张压134 mmHg,无不良反应。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种调理血压的药食同源食品,其特征在于,按照重量百分比由如下原料制成:硫辛酸2~4%;L-精氨酸30~42%;L-瓜氨酸30~42%;三七提取物2~6%;辅料36~6%,各组分含量百分数之和等于100%。
2.根据权利要求1所述调理血压的药食同源食品,其特征在于,所述三七提取物取自三七植物,包括但不限于三七花、三七茎叶的一种或多种。
3.根据权利要求1所述调理血压的药食同源食品,其特征在于,所述L-精氨酸提取自豆类、瓜类、坚果类或谷类,包括但不限于红豆、绿豆、黄豆、黑豆、白芸豆、南瓜、冬瓜子、南瓜子、花生、核桃、燕麦、芝麻的一种或多种。
4.根据权利要求1所述调理血压的药食同源食品,其特征在于,所述L-瓜氨酸提取自瓜类或坚果类,包括但不限于西瓜、丝瓜、冬瓜、南瓜、黄瓜、甜瓜、核桃的一种或多种。
5.根据权利要求1所述调理血压的药食同源食品,其特征在于,所述辅料包括但不限于木糖醇、甘油、山梨醇、阿斯巴甜、三氯蔗糖、山梨酸钾、苯甲酸钠、淀粉和麦芽糊精等常见功能食品辅料中的一种或多种。
6.根据权利要求1所述调理血压的药食同源食品,其特征在于,所述α-硫辛酸提取自菠菜。
7.根据权利要求1-6任一所述调理血压的药食同源食品的制备方法,其特征在于:包括如下步骤:
1) 按照权利要求1的比例配备原料,对其中需要粉碎的原料进行粉碎至100-200目;
2) 将上述已称取的原料放入粉末搅拌机搅拌均匀;
3) 成品:将搅拌均匀的混合粉料通过压片机制成片剂,装入包装袋或瓶子,即为成品。
8.根据权利要求7所述调理血压的药食同源食品的制备方法,其特征在于,三七提取物的制备步骤如下:
(1)将三七花或三七茎叶在55℃条件下烘干至恒重;
(2)将烘干后的三七花或三七茎叶粉碎,加入3倍量浓度95%的乙醇,在70℃条件下搅拌2.5h后过滤,收集滤液;
(3)将滤液在70℃条件下减压浓缩,得到浓缩提取液,转移至十万级洁净区内;
(4)洁净区内将减压浓缩提取液喷雾干燥,温度为105℃,喷出速度为0.6 L/s,之后将喷雾干燥收集的固体提取物粉碎,以100目振动筛除去大颗粒,收集筛下物即为三七提取物。
9.一种如权利要求1-8任一所述调理血压的药食同源食品在制备调理血压食品中的应用,用量小于3g/天/人,达到调理血压的效果。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910300571.XA CN109998117A (zh) | 2019-04-15 | 2019-04-15 | 调理血压的药食同源食品及制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910300571.XA CN109998117A (zh) | 2019-04-15 | 2019-04-15 | 调理血压的药食同源食品及制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109998117A true CN109998117A (zh) | 2019-07-12 |
Family
ID=67171948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910300571.XA Pending CN109998117A (zh) | 2019-04-15 | 2019-04-15 | 调理血压的药食同源食品及制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109998117A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110384724A (zh) * | 2019-09-03 | 2019-10-29 | 沂水家世诺教育科技有限公司 | 一种富含l-精氨酸的花生提取物、具有降血压功效的组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101697989A (zh) * | 2009-11-20 | 2010-04-28 | 许淑清 | 三七及其提取物在制备治疗和/或预防冠状动脉粥样硬化药物的用途 |
CN103006730A (zh) * | 2012-12-31 | 2013-04-03 | 丁家宜 | 促进一氧化氮生成的用于心血管病防护的含精氨酸、三七提取物的组合物 |
-
2019
- 2019-04-15 CN CN201910300571.XA patent/CN109998117A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101697989A (zh) * | 2009-11-20 | 2010-04-28 | 许淑清 | 三七及其提取物在制备治疗和/或预防冠状动脉粥样硬化药物的用途 |
CN103006730A (zh) * | 2012-12-31 | 2013-04-03 | 丁家宜 | 促进一氧化氮生成的用于心血管病防护的含精氨酸、三七提取物的组合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110384724A (zh) * | 2019-09-03 | 2019-10-29 | 沂水家世诺教育科技有限公司 | 一种富含l-精氨酸的花生提取物、具有降血压功效的组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030224062A1 (en) | Food supplements containing 4-hydroxyisoleucine and creatine | |
CN106174474A (zh) | 一种适用于心脑血管疾病患者食用的特膳食品 | |
CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
EP2990048B1 (en) | Nitric oxide concentration elevating agent | |
CN106689948A (zh) | 一种胶原蛋白复合亚麻酸饮料及其制备方法 | |
CN101715989B (zh) | 一种营养鸡汤冻及其制做方法 | |
CN104415188A (zh) | 一种左旋肉碱茶多酚胶囊及其制备方法 | |
CN109998117A (zh) | 调理血压的药食同源食品及制备方法和应用 | |
CN107156747A (zh) | 一种虫草核桃肽营养粉及其制备方法 | |
CN102429302B (zh) | 一种含有银杏的保健饮料及其加工工艺 | |
CN106509561A (zh) | 一种亚麻乳饮料及其制作方法 | |
CN103960611B (zh) | 一种富含维生素c的复合猕猴桃口含片及制备方法 | |
CN103263054B (zh) | 一种降血压功能性饮品 | |
CN101653278A (zh) | 花生茯苓浆饮品及方法 | |
CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 | |
CN102599512B (zh) | 一种沙棘营养粉及其制备方法 | |
CN104687118A (zh) | 营养型减肥速溶粉 | |
CN107440113A (zh) | 纸上活体综合胚芽功能性微量激活源及其制备方法 | |
CN106617109A (zh) | 一种肝病改善治疗的功能营养组合物及其制备方法 | |
CN109805128A (zh) | 一款玛咖茶植物饮品及其制备方法 | |
CN105995980A (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
KR20090018874A (ko) | 고혈압 환자가 마시는 새콤달콤한 진 코 침출 및 액상 티 조성물과 그 제조방법 | |
CN106901082A (zh) | 沙棘甲壳素防三高饮料 | |
KR20090021410A (ko) | 피로할 때 마시는 대추 침출 차 조성물과 그 제조방법 | |
CN104957464A (zh) | 一种荷香蜂蜜干粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |